Trial ID or NCT#

NCT02429804

Status

recruiting iconRECRUITING

Purpose

This pilot clinical trial studies combined fluorine F 18 sodium fluoride (NaF)/ fludeoxyglucose F 18 (FDG) positron emission tomography (PET) and magnetic resonance imaging (MRI) in measuring response to a drug, radium Ra 223 dichloride (Ra-223), in treating patients with prostate cancer that has not responded to hormone therapy and has spread to other parts of the body. Combining NaF/FDG in a simultaneous PET/MRI scan may help doctors accurately measure how well patients respond to treatment with radium Ra 223 dichloride.

Official Title

Combined "One Stop Shop" NaF/FDG PET/MRI Evaluation of Response to Xofigo® in mCRPC Patients: A Pilot Study

Eligibility Criteria

Ages Eligible for Study: Older than 19 Years
Sexes Eligible for Study: Male
Accepts Healthy Volunteers: No

Investigator(s)

Andrei Iagaru
Andrei Iagaru
Radiologist
Professor of Radiology (Nuclear Medicine) at the Stanford University Medical Center
Sandy Srinivas
Sandy Srinivas
Medical oncologist, Urologic specialist, Genitourinary specialist
Professor of Medicine (Oncology) and, by courtesy, of Urology at the Stanford University Medical Center

Contact us to find out if this trial is right for you.

CONTACT

Omar Rutledge
(650) 721-4089